Recent Business Highlights

Biosimilars and small molecule Oncology assets fueling global expansion Successful launches of Oncology products in EM and EU • Colombia, Brazil, Algeria, Spain, Italy Reditux™ paving the way for the entry of upcoming Biosimilar assets in new markets • Currently approved in 17 countries and available in 14 Launched five products in India through strategic collaboration with Amgen Vectibix XGEVA Kyprolis (panitumumab) (denosumab) injection Injection for IV Infusion (carfilzomib) f for Injec prolia (denosumab injection Repatha (evolocumab) 140 mg/ml injection Entry into more new markets in LatAm, Africa and Asia slated for H2 FY 18 12

View entire presentation